Elebrato Ellipta 유럽 연합 - 영어 - EMA (European Medicines Agency)

elebrato ellipta

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - elebrato ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Trelegy Ellipta 유럽 연합 - 영어 - EMA (European Medicines Agency)

trelegy ellipta

glaxosmithkline trading services - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trelegy ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Trelegy Ellipta 92microgramsdose  55microgramsdose  22microgramsdose dry powder inhaler 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

trelegy ellipta 92microgramsdose 55microgramsdose 22microgramsdose dry powder inhaler

glaxosmithkline uk ltd - fluticasone furoate; vilanterol trifenatate; umeclidinium bromide - inhalation powder - 92microgram/1dose ; 22microgram/1dose ; 65microgram/1dose

Temybric Ellipta 유럽 연합 - 영어 - EMA (European Medicines Agency)

temybric ellipta

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - temybric ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).

TRELEGY ELLIPTA INHALATION POWDER 100 MCG62.5 MCG25 MCG 싱가포르 - 영어 - HSA (Health Sciences Authority)

trelegy ellipta inhalation powder 100 mcg62.5 mcg25 mcg

glaxosmithkline pte ltd - fluticasone furoate (micronised); umeclidinium bromide (micronised) 74.2 mcg eqv to umeclidinium; vilanterol trifenatate (micronised) 40 mcg eqv to vilanterol - powder, metered - fluticasone furoate (micronised) 100 mcg; umeclidinium bromide (micronised) 74.2 mcg eqv to umeclidinium 62.5 mcg; vilanterol trifenatate (micronised) 40 mcg eqv to vilanterol 25 mcg

TRELEGY ELLIPTA POWDER 캐나다 - 영어 - Health Canada

trelegy ellipta powder

glaxosmithkline inc - fluticasone furoate; umeclidinium (umeclidinium bromide); vilanterol (vilanterol trifenatate) - powder - 100mcg; 62.5mcg; 25mcg - fluticasone furoate 100mcg; umeclidinium (umeclidinium bromide) 62.5mcg; vilanterol (vilanterol trifenatate) 25mcg - antimuscarinics antispasmodics

TRELEGY ELLIPTA 92  55  22 MCG 이스라엘 - 영어 - Ministry of Health

trelegy ellipta 92 55 22 mcg

glaxo smith kline (israel) ltd - fluticasone furoate; umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation pre-dispensed - vilanterol as trifenatate 22 mcg/inh; umeclidinium as bromide 55 mcg/inh; fluticasone furoate 92 mcg/inh - vilanterol, umeclidinium bromide and fluticasone furoate - asthmatrelegy ellipta 92/55/22 mcg is indicated for the maintenance treatment of asthma in patients aged 18 years and older.trelegy ellipta 92/55/22 mcg should be prescribed for patients who are not adequately controlled on maintenance asthma medication, such as an ics/laba.important limitations of use:trelegy ellipta 92/55/22 mcg is not indicated for the relief of acute asthma.copd (chronic obstructive pulmonary disease)trelegy ellipta 92/55/22 mcg is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.

TRELEGY ELLIPTA POWDER 캐나다 - 영어 - Health Canada

trelegy ellipta powder

glaxosmithkline inc - fluticasone furoate; umeclidinium (umeclidinium bromide); vilanterol (vilanterol trifenatate) - powder - 200mcg; 62.5mcg; 25mcg - fluticasone furoate 200mcg; umeclidinium (umeclidinium bromide) 62.5mcg; vilanterol (vilanterol trifenatate) 25mcg - antimuscarinics antispasmodics

TRELEGY ELLIPTA 184  55  22 MCG 이스라엘 - 영어 - Ministry of Health

trelegy ellipta 184 55 22 mcg

glaxo smith kline (israel) ltd - fluticasone furoate; umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation pre-dispensed - vilanterol as trifenatate 22 mcg/inh; umeclidinium as bromide 55 mcg/inh; fluticasone furoate 184 mcg/inh - vilanterol, umeclidinium bromide and fluticasone furoate - asthmatrelegy ellipta 184/55/22 mcg is indicated for the maintenance treatment of asthma in patients aged 18 years and older. trelegy ellipta 184/55/22 mcg should be prescribed for patients who are not adequately controlled on maintenance asthma medication, such as an ics/laba.important limitations of usetrelegy ellipta 184/55/22 mcg is not indicated for the relief of acute asthma.trelegy ellipta 184/55/22 mcg is not indicated for patients with copd.